In the News

7 August 2019
Q&A with Pulmocide CEO Garth Rapeport – Why Pulmocide is developing targeted lung therapy.

Author: Jess Young

Publication: SWNS

In a Q&A interview, Garth Rapeport, CEO of SV portfolio company Pulmocide, explains why the company is developing inhaled medications for viral and fungal infections and offers advice to startup biopharma companies based on his experience from working with firms like SV.

View the article

Q&A with Pulmocide CEO Garth Rapeport – Why Pulmocide is developing targeted lung therapy.